Its close association with survival decline has promoted it to be a powerful prognostic and predictive biomarker in breast cancer, and therapies targeting the overexpressed HER2/neu peptides or function are one of the most studied breast cancer therapeutics (Iqbal and Iqbal 2014). This evidence concerns the gene ERBB2 and breast carcinoma.